| Recruiting | A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People NCT07238816 | Novo Nordisk A/S | Phase 1 |
| Recruiting | A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haem NCT07220564 | Novo Nordisk A/S | Phase 1 |
| Recruiting | Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients NCT06574984 | Novo Nordisk A/S | — |
| Completed | A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men NCT06649630 | Novo Nordisk A/S | Phase 1 |
| Enrolling By Invitation | Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A o NCT06285071 | Novo Nordisk A/S | — |
| Recruiting | Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. NCT07437404 | Sinocelltech Ltd. | Phase 3 |
| Recruiting | Prevalence of Synovitis in Patients With Haemophilia A NCT06352216 | University Hospital, Bonn | — |
| Completed | A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRO NCT05878938 | Novo Nordisk A/S | Phase 3 |
| Active Not Recruiting | A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) NCT05685238 | Novo Nordisk A/S | Phase 3 |
| Completed | A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector o NCT05681845 | Novo Nordisk A/S | Phase 1 |
| Recruiting | An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoc NCT05621746 | Novo Nordisk A/S | — |
| Completed | A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors NCT05053139 | Novo Nordisk A/S | Phase 3 |
| Completed | Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Pre NCT05082116 | Novo Nordisk A/S | Phase 3 |
| Completed | Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities NCT04584892 | Novo Nordisk A/S | — |
| Completed | Post-Marketing Surveillance (Use-results Surveillance) With Esperoct® NCT04334057 | Novo Nordisk A/S | — |
| Enrolling By Invitation | Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol NCT04682145 | Novo Nordisk A/S | — |
| Enrolling By Invitation | A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® NCT04574076 | Novo Nordisk A/S | — |
| Completed | An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, i NCT04165135 | Hoffmann-La Roche | — |
| Completed | A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explor NCT03741881 | Novo Nordisk A/S | — |
| Completed | Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophili NCT03276130 | Swedish Orphan Biovitrum | — |
| Completed | A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children NCT03660774 | Novo Nordisk A/S | — |
| Completed | Register of Patients With haEmophilia A tReated With Afstyla® NCT04675541 | CSL Behring | — |
| Completed | Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients NCT03179748 | Novo Nordisk A/S | — |
| Terminated | Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haem NCT03588741 | Novo Nordisk A/S | Phase 3 |
| Completed | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People Wi NCT03528551 | Novo Nordisk A/S | Phase 3 |
| Completed | Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alf NCT03449342 | Novo Nordisk A/S | Phase 4 |
| Recruiting | Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemo NCT03695978 | Octapharma | — |
| Completed | A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Ha NCT03196297 | Novo Nordisk A/S | Phase 2 |
| Completed | A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia NCT03055611 | Swedish Orphan Biovitrum | — |
| Completed | Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients NCT02994407 | Novo Nordisk A/S | Phase 1 |
| Completed | Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treate NCT02938585 | Novo Nordisk A/S | Phase 3 |
| Completed | Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophili NCT02941354 | Novo Nordisk A/S | Phase 1 |
| Completed | A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinet NCT02920398 | Novo Nordisk A/S | Phase 1 |
| Unknown | TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia NCT02781766 | Hospices Civils de Lyon | N/A |
| Completed | Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to NCT02490787 | Novo Nordisk A/S | Phase 1 |
| Completed | Thrombin Generation Numerical Models Validation in Haemophilic Case NCT02300519 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Terminated | Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemoph NCT01811875 | Bio Products Laboratory | Phase 4 |
| Completed | To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives NCT02241694 | Novo Nordisk A/S | — |
| Completed | To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan NCT02207218 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A NCT02137850 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia NCT02035384 | Novo Nordisk A/S | — |
| Completed | A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care NCT02049099 | Swedish Orphan Biovitrum | — |
| Completed | Project to Update the Study of Congenital Haemophilia in Spain NCT01959555 | Novo Nordisk A/S | — |
| Withdrawn | Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects NCT02084810 | Novo Nordisk A/S | Phase 1 |
| Completed | Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia NCT01988532 | Novo Nordisk A/S | — |
| Completed | A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B NCT01949792 | Novo Nordisk A/S | Phase 1 |
| Completed | A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-10 NCT01731600 | Novo Nordisk A/S | Phase 3 |
| Completed | Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A NCT01692925 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children NCT01493778 | Novo Nordisk A/S | Phase 3 |
| Completed | Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophili NCT01489111 | Novo Nordisk A/S | Phase 3 |
| Terminated | A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynami NCT01631942 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjec NCT01555749 | Novo Nordisk A/S | Phase 1 |
| Completed | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Tre NCT01480180 | Novo Nordisk A/S | Phase 3 |
| Completed | Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries NCT01503567 | Novo Nordisk A/S | — |
| Completed | Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients NCT01436825 | Bayer | — |
| Completed | BAY81-8973 Pediatric Safety and Efficacy Trial NCT01311648 | Bayer | Phase 3 |
| Completed | Survey Evaluating the Psychosocial Effects of Living With Haemophilia NCT01322620 | Novo Nordisk A/S | — |
| Completed | A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A NCT01365520 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male NCT01272206 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or NCT01288391 | Novo Nordisk A/S | Phase 1 |
| Completed | Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B NCT01220141 | Novo Nordisk A/S | — |
| Completed | A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to T NCT01238367 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B NCT01228669 | Novo Nordisk A/S | Phase 1 |
| Completed | Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bl NCT01234545 | Novo Nordisk A/S | — |
| Completed | Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A NCT01205724 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A NCT01138501 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subj NCT00984126 | Novo Nordisk A/S | Phase 3 |
| Completed | A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Re NCT00951873 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Facto NCT00922792 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects NCT00840086 | Novo Nordisk A/S | Phase 3 |
| Completed | Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects NCT00837356 | Novo Nordisk A/S | Phase 1 |
| Completed | Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy NCT00638001 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 4 |
| Completed | Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the U NCT00853086 | Novo Nordisk A/S | — |
| Completed | Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds NCT00486278 | Novo Nordisk A/S | Phase 2 |
| Recruiting | A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI NCT02207894 | Haemophilia Centre Rhine Main | — |
| Completed | Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia P NCT01562457 | Novo Nordisk A/S | Phase 1 |
| Completed | Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes. NCT00245297 | Recoly N.V. | Phase 2 |
| Completed | A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia NCT02246894 | Bio Products Laboratory | Phase 3 |
| Completed | Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B i NCT01562587 | Novo Nordisk A/S | Phase 1 |
| Completed | An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery NCT02250482 | Bio Products Laboratory | Phase 3 |
| Completed | An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients. NCT02246868 | Bio Products Laboratory | Phase 3 |